Patent cliffs & loss of exclusivity
EyePoint is a clinical-stage biopharmaceutical company developing sustained-release treatments for serious retinal diseases. Its lead investigational program, DURAVYU (vorolanib intravitreal insert, formerly EYP-1901), combines a tyrosine kinase inhibitor with its bioerodible Durasert E delivery technology and is in Phase 3 development for wet age-related macular degeneration and diabetic macular edema. Headquartered in Watertown, Massachusetts, EyePoint traces its corporate predecessor to pSivida Limited, formed in 2000, and adopted the name EyePoint, Inc. in December 2025.
| Legal Name | EyePoint Pharmaceuticals, Inc. |
|---|---|
| Company Operating Status | Active |
| Crunchbase URL | https://www.crunchbase.com/organization/psivida |
| Facebook URL | https://www.facebook.com/EyePointPharma/ |
| Fax Number | 617.926.5050 |
| Full Address | 480 Pleasant Street, Suite A-210 Watertown, MA 02472 United States |
| LinkedIn URL | https://www.linkedin.com/company/eyepointbio |
| Pitchbook URL | https://pitchbook.com/profiles/company/41590-45 |
Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.